What question did this study set out to answer?

This review aims to analyze treatment regimens and response rates in early triple-negative breast cancer (TNBC) based on real-world practices.

April 10, 2026Open Access

Treatment Regimens and Response Rates in Early TNBC: A Review of Real‐World Practice in the Second Decade of the 21st Century

Key Points

This review aims to analyze treatment regimens and response rates in early triple-negative breast cancer (TNBC) based on real-world practices.
Reviewed clinical trial evidence
Analyzed implementation of treatments
Examined early TNBC patient outcomes
Higher rates of pathologic complete response (pCR) observed in clinical practice
Successful incorporation of clinical trial findings into real-world treatments
Future focus will be on immune checkpoint inhibitors in treatment approaches

Abstract

The evidence from clinical trials was quickly incorporated into clinical practice, leading to higher pCR rates and benefits for patients. In the next step, the implementation of immune checkpoint inhibitors in real-world practice will be analyzed.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Hatzipanagiotou et al. (Thu,) studied this question.

synapsesocial.com/papers/69d8962d6c1944d70ce07641 https://doi.org/https://doi.org/10.1155/tbj/9970072

Bookmark

View Full Paper